

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

26th February 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani

Notice Regarding the Initiation of Expansion Cohorts for rogocekib

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) today announced that, following the recommendation of the Independent Safety Review Committee for the ongoing Phase 1/2 clinical trial of rogocekib in the United States, the Company has decided to initiate the expansion cohorts.

Chordia is currently conducting dose-escalation cohorts in a Phase 1/2 clinical trial of rogocekib in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in the United States. As a result of the administration of rogocekib to 42 patients to date, the dose-level cohort defined by the dose and regimen that met the predefined safety and efficacy criteria for transition to the expansion cohorts, as specified in the clinical trial protocol, was confirmed. These findings were reviewed by the Independent Safety Review Committee, which subsequently recommended proceeding to the expansion cohorts at the identified dose level for continued evaluation.

The expansion component comprises two stages—Initial Expansion (IE cohort) and Additional Expansion (AE cohort)—planned in accordance with the U.S. FDA’s Project Optimus guidance.

In the first stage, the IE cohort, patients with relapsed or refractory AML and MDS will be enrolled to evaluate safety and efficacy while maintaining an appropriate balance between the two disease populations. Multiple dose and regimen options are planned for assessment in this cohort. Data from the ongoing dose-escalation phase will be analyzed sequentially, and based on these results, approximately 30 patients will receive rogocekib at the selected candidate doses and regimens to further define conditions for subsequent evaluation.

In the second stage, the AE cohort, an in-depth assessment will be conducted using the dose, regimen, and target tumor type selected based on the IE cohort results, with the objective of further establishing the safety and efficacy required to advance rogocekib into a Phase 2 clinical study.

A comprehensive evaluation of the AE cohort outcomes will be used to determine the Recommended Phase 2 Dose (RP2D) and the target tumor type for the Phase 2 trial.

Chordia currently anticipates initiating the Phase 2 clinical trial around mid-2027.

The results from the dose-escalation cohorts are planned for presentation at an international scientific conference in mid-2026, and further details will be provided once finalized.

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chorditherapeutics.com/en/>.